Lineage Cell Therapeutics Inc (LCTX)

[terry hallinan]

BioTime Licenses GMP Cell Line to Goliver Therapeutics

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has licensed one of its pluripotent cell lines to Goliver Therapeutics, a France-based company focused on addressing liver diseases with regenerative technologies.

...This commercial license allows Goliver to build upon its pre-clinical work with our line to produce their cells for commercial use.

The terms of the agreement were undisclosed, but include an upfront payment, potential development milestone payments and royalties on sales of commercialized products.

https://investorshub.advfn.com/secure/post_new.aspx?board_id=6754

The only reasons I can think of for omitting details are:

1. Agreement remains tentative despite commitments.

2. Regulatory approval(s) are needed.

3. Adjustments to AgeX spin-off are needed.

Best, Terry